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1Introduction
Cytochrome b5 reductase (CyB5R, EC 1.6.2.2) is a 
member of the flavoprotein transhydrogenase family of 
oxidoreductase enzymes and is present as a relatively 
high concentration in liver tissues. This protein catalyzes 
the single electron reduction of ferricytochrome b5 to 
ferrocytochrome b5 using electrons from NADH, the 
preferred physiological pyridine-type electron donor, 
using its FAD domain. The three-dimensional structure of 
the protein reveals two distinct highly conserved regions 
called the FAD and NADH domains. The FAD domain has 
a large cleft in which the FAD prosthetic group is located, 
and the NADH domain provides a suitable position for the 
NADH coenzyme. The N-terminus of the NADH domain 
plays a hinge-connecting role between the two domains. 
CyB5R exists in two forms. The dominant isoform is an 
amphipathic microsomal membrane-bound variant 
consisting of a small hydrophobic membrane-anchoring 
domain of approximately 3 kD and one larger hydrophilic 
catalytic domain of approximately 31 kD. The other 
isoform is a truncated soluble cytoplasmic protein that 
consists of the flavin catalytic domain only. Previous 
studies have shown that the soluble and membrane-
bound variants of CyB5R are both encoded by the same 
gene and are products of alternative splicing (Pietrini 
et al., 1988). The amphipathic isoform is embedded in 
the plasma membrane and in the membranes of the 
endoplasmic reticulum, mitochondria, Golgi apparatus, 
peroxisomes, nucleus, sarcoplasmic reticulum, and 
neuronal synapses, and it has been shown to be a critical 
component of the microsomal electron transport system. 
This protein, together with the membrane-bound form 
of cytochrome b5 (CyB5), is involved in a variety of 
metabolic functions, including xenobiotics metabolism 
and detoxification (Rhoads et al., 2011; Abouraya et al., 
2011); bioactivation of carcinogenic drugs (Sangeetha 
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et al., 2012); bioactivation of anticancer drugs; fatty acid 
elongation and desaturation; cholesterol anabolism; 
metmyoglobin reduction; and redox signaling in neurons 
(Mirzaei, 2010). In contrast, the soluble isoform of CyB5R 
exists mainly in mammalian circulating erythrocytes 
and is important for the reduction of methemoglobin 
to hemoglobin, thereby effectively regulating the 
methemoglobin concentration in these cells. Functional 
deficiency in the protein isoforms of CyB5R is known as 
recessive congenital methemoglobinemia disease, the 
first disease to be directly associated with an enzyme 
deficiency. Patients are especially susceptible to toxic 
methemoglobinemia resulting from the ingestion of 
oxidant drugs (Percy et al., 2005b).
Cytochrome b5 reductase enzymes have been reported 
in a wide variety of eukaryotes including humans, mam-
mals, plants, birds, fish, amphibians, worms, insects, 
fungi, yeasts, and protozoa, and many of these enzymes 
have been studied genetically, enzymatically, and struc-
turally. In the literature, the specific activity (kcat) of puri-
fied functional native enzyme is reported to range from a 
minimum of 368 s−1 (human) to a maximum of 1060 s−1 
(bovine variant) (Roma et al., 2006). To date, CyB5R has 
not been comprehensively reviewed. Here, we provide a 
summary of the enzymology, diversity, structure, kinet-
ics, mechanism of action, possible roles, and potential 
for industrial applications of this enzyme.
Phylogenetics of cyB5R
CyB5R is a member of the NAD(P)H-ferredoxin reduc-
tase (FNR) super-family that was initially called NADH-
diaphorase (Scott & Griffith, 1959); this protein was later 
determined to include dihydronicotinamide adenine 
dinucleotide-cytochrome b5 reductase, reduced nicotin-
amide adeninedinucleotide-cytochrome b5 reductase, 
NADH-ferricyanide reductase, NADH-ferricytochrome 
b5 oxidoreductase, NADH 5α-reductase, NADH-
dehydrogenase, and NADH-methemoglobin reductase. 
Sequence alignment identified significantly similar 
molecular structures and strong homologies between 
CyB5R and the other enzymes in the FNR super-family, 
such as NADPH-cytochrome P450 reductase, NAD(P)
H-ferredoxin reductase, NAD(P)H-nitrate reductase, 
nitric oxide synthase, methionine synthase reductase, 
NADPH-flavodoxin reductase, NADPH-sulfite reduc-
tase, and phthalate dioxygenase reductase. With regard 
to function, the FNR super-family contains highly con-
served flavin- and nucleotide-binding domains. The 
conservation of the GxGxxP, CGxxxM, RxY(T/S)xx(S/N) 
and (G/R)xx(S/T) motifs, which are associated with the 
FNR flavoprotein family, demonstrates their importance 
in interactions with the flavin cofactor and pyridine 
coenzyme. The CyB5R motifs from a variety of eukary-
otes are illustrated in Figure 1. The human diaphorase 
1 (DIA-1; GenBank ID: NC000022.10) gene that codes 
CyB5R consists of nine exons and eight introns. This 
gene, with a total length of 31,560 nucleotides, is located 
on chromosome 22q13.2-q13.31, from −43013845 to 
−43045404 nts. Extensive homology studies on DIA-1 
revealed that two alternative mRNAs can be transcribed 
from this gene (Bulbarelli et al., 1998). The longer tran-
script consists of all nine exons and codes for 301 amino 
acids (1MGAQLSTL … TERCFVF301), including the initia-
tor methionine, with a molecular mass of 34.1 kD. This 
N-myristoylated enzyme is found in almost all tissues; 
however, the second conserved AUG (M24) codon in 
exon 2 also initiates transcription efficiently but is used 
in only erythrocytes. This alternative erythrocyte-specific 
transcript (24MKLFQRSTPA …TERCFVF301) consists of 
exons 2–9. The first 23 N-terminal hydrophobic amino 
acids of the full protein are subsequently removed, and 
the remaining 278 amino acids give a total mass of 31.6 
kD (Leroux et al., 2001).
Structure of cyB5R (NMR spectroscopy and 
crystallography)
The three-dimensional (3D) structure of CyB5R has been 
solved and refined using X-ray crystallography. This 
structure has provided important information regard-
ing the function of the enzyme and its role in electron 
transport from NADH to the other enzyme complexes. 
The first successful X-ray structure was provided by Miki 
et al. (Miki et al., 1987). Currently, there are five 3D struc-
tures of CyB5R that have been submitted to the protein 
data bank (PDB: http://www.pdb.org/pdb). Crystals of 
the soluble isoform of CyB5R are usually grown using 
the sitting or hanging drop methods. A protein solution 
and a reservoir (containing a stabilizer such as glycerol 
and a precipitant such as ammonium sulfate or PEG in 
buffer) are mixed. Crystals grow as orthorhombic prisms 
over a few days (Bewley et al., 2003). The soluble CyB5R 
diffraction map (Figure 2) reveals two distinct domains: 
the N-terminal FAD binding domain (from I34 to R143), 
which contains a binding site for the FAD prosthetic 
group, and the NADH domain (residues K173 to F301). 
These domains are separated by a large interdomain cleft 
(G144-V172) known as a hinge region (Bando et al., 2004, 
Kim et al., 2007). The three anti-parallel β-sheets in the 
hinge region keep the two lobes in close proximity with 
the correct conformational orientation. This orientation 
appears to be critical for electron transfer from NADH 
to FAD. The FAD domain consists of six anti-parallel 
β-sheets and one α-helix with the order 5β/1α/1β. The 
NADH domain forms a α/β/α structure consisting of five 
β-strands and four α-helices (Nishida et al., 1995).
In contrast, needle-shaped crystals of membrane-
CyB5R are normally too small for high-resolution X-ray 
diffraction studies (Miki et al., 1987). Membrane proteins 
comprise approximately 20–30% of the total proteome; 
however, only a few structures have been resolved. A large 
α-helix-type hydrophobic domain (of more than 15% of 
the total protein size) prohibits the application of stan-
dard structural biology techniques. Most X-ray diffrac-
tion patterns from membrane-CyB5R rely on truncated 
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solubilized enzyme (the hydrophobic membrane anchor 
is cleaved off, and the soluble part is then crystallized). 
The highly flexibility, hydrophobicity, and conforma-
tional inhomogeneity of its transmembrane domain 
makes the enzyme prone to aggregation and misfolding 
and makes it very difficult to obtain stable crystals of 
good quality. The transmembrane domain influences 
the enzyme function, so this domain is essential for an 
accurate 3D-structure of the protein; therefore, a com-
plete understanding of its structure and function can be 
achieved only by studying the complete molecule (Durr 
et al., 2007). Although solid-state NMR spectroscopy of 
CyB5R has not yet been reported, this technique is now a 
well-established approach for achieving excellent spec-
tral resolution for noncrystalline and amorphous mole-
cules such as membrane-associated proteins (see http://
blanco.biomol.uci.edu/mpstruc/listAll/list). Uniform 
isotopic labeling is the most critical stage in successful 
solid-state NMR spectroscopy. Common isotopic radio-
nuclides used for the study of proteins include 15N from 
labeled amino acids and 13C from labeled glucose that are 
incorporated into the protein structure during heterolo-
gous protein expression (Opella & Marassi, 2004).
Mechanism of action
The general name “NADH-dependent oxidoreductase” 
applies to every enzyme that transfers electrons from 
the pyridine moiety to an acceptor. A great deal of our 
knowledge of the enzyme kinetics and mechanism of 
electron transfer comes from crystal structure studies 
and site-directed mutagenesis. Although CyB5R transfers 
electrons to a variety of electron acceptor molecules such 
as ferricyanide, dehydroascorbate, and quinones, the 
ferric atom of the heme cofactor within CyB5 is the most 
natural substrate for reduction. A functional 1:1 complex 
between CyB5R and CyB5 in humans has been verified. 
The electrostatic interactions between the lysyl residues 
(K42, K126, K163, and K164) in CyB5R and the carboxyl 
groups (E47, E48, E52, E60, and D64) of CyB5 keep these 
Figure 1. Multiple sequence alignment of CyB5R primary structure. Full-length, membrane-associated form of CyB5R retrieved from GenBank 
(Homo sapiens, GenBank ID: NP_000398.6, Bos Taurus, GenBank ID: NP_001096720.1, Arabidopsis thaliana, GenBank ID: NP_197279.1, 
Aspergillus flavus, GenBank ID: XP_002379810.1, and Saccharomyces cerevisiae, GenBank ID: Z28365). Sequence conservation comparisons 
were carried out by generating the ClustalW2 algorithm using the optimized EMBL-EBI model (EBI: http://www.ebi.ac.uk/Tools/web_
clustalw2). Conserved sequences that show the FAD binding motifs “RxY(T/S)xx(S/N) and (G/R)xx(S/T)” are boxed. The conserved residues 
detected within NAD binding “GxGxxP and CGxxxM” motifs are boxed and underlined. The down arrow denotes the end of the hydrophobic 
anchoring sequence of the human protein. Consensus alignment symbols (*), (:), (.), and (-) represent identical, strong similar, weak similar, 
and gap, respectively. (See colour version of this figure online at www.informahealthcare.com/bty)
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proteins tightly complexed and are suitable for electron 
transfer (Shirabe et al., 1998). Asada et al. proposed that 
R92 and R143 also participate in the CyB5/CyB5R inter-
action (Asada et al., 2009). Electron transfer is conducted 
according to the experimentally proposed thermody-
namic principles of energy levels. The redox potential 
differences between the FAD and NAD complexes are 
approximately −60 mV; therefore, CyB5R can participate 
in one or two electron transfers to a new electron accep-
tor and electrons can move efficiently through the elec-
trochemical gradient (Iyanagi et al., 1984). As shown in 
Figure 3, the sequence of this transfer is summarized as 
follows: 2e- from NADH → CyB5R → FAD → reduction of 2 
CyB5 →electron transfer to desaturase, CyP450 or methe-
moglobin. The flavin reduction step has been shown to 
be the rate-limiting factor of this chain reaction (Kimura 
et al., 2003). CyB5R domains consist of highly conserved 
motifs. The NADH domain motif, 181GxGxxP186, gener-
ates a flat surface in the polypeptide backbone in which 
NADH can rest in the correct orientation (Bewley et al., 
2003). G181 and G183 participate in hydrophobic inter-
actions with the nicotinamide ring, while the isoalloxa-
zine ring of FAD forms two hydrogen bonds with T185. 
T182 and P186 also contribute to hydrophobic interac-
tions with the isoalloxazine ring by bringing the FAD 
prosthetic group sufficiently close to the nicotinamide 
ring of NADH (Roma et al., 2005; Asada et al., 2008). 
Although the 274CGxxxM279 motif in the NADH domain 
has not been demonstrated to participate in any direct 
electrostatic or hydrogen bond contacts, it provides the 
correct orientation for NADH for efficient hydride trans-
fer (Percy et al., 2006a). Although NADH is the preferred 
electron donor for CyB5R, a D239T mutation will change 
this preference to one for NADPH. The reduction in 
negative charges due to this mutation appears to be the 
reason for this change (Marohnic et al., 2003). The flavin 
binding 92RxY(T/S)xx(S/N)98 motif and the FAD/FMN 
selectivity motif 125(G/R)xx(S/T)128 are highly conserved 
among all of the flavoprotein family members and have 
been clearly shown to be structurally important for flavin 
cofactor interaction and electron transfer within CyB5R 
(Kimura et al., 2001; Marohnic et al., 2005).
Purification
Regardless of its total protein (mitochondrial, lysosomal, 
etc.) origin, two main protocols can be used to purify 
native membrane-bound CyB5R. The detergent-solu-
bilized method uses different detergents to solubilize 
the amphipathic enzyme intact. An aqueous solution 
of Triton X-100, Triton X-114, Emulgen 913, cholate, 
CHAPS, and n-dodecyl β-D-maltoside or an ethanol 
solution of digitonin has been reported for membrane 
CyB5R solubilization and extraction. Following adequate 
incubation periods at 4°C and high-speed centrifugation, 
the solubilized portion is removed for chromatography. 
Ion exchange chromatography with DEAE-cellulose, 
Figure 2. The X-ray crystallographic structure of Rattus norvegicus 
cytochrome b5 reductase (PDB: 1IBO). The ribbon diagram of 
the three-dimensional rat CyB5R enzyme generated using the 
Swiss-PDB viewer 4.0.3 program (ExPASy tools: http://ExPASy.
org/spdbv). The FAD-binding domain (left), the NADH-binding 
domain (right) and the connecting ‘‘hinge’’ region are depicted 
in red, blue, and black, respectively. Arrows represent β-stranded 
configurations, and α-helices are shown as coils. (See colour 
version of this figure online at www.informahealthcare.com/bty)
Figure 3. Schematic diagram of electron and proton transfer by the CyB5R complex. The isoalloxazine ring of FAD receives two electrons 
from NADH by a hydride transfer mechanism. Conformational changes in the flavin lobe of the enzyme make it ideal for reaching the heme 
group in CyB5. These electrons then reduce two equivalents of ferric atoms to ferro ions. (See colour version of this figure online at www.
informahealthcare.com/bty)
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DEAE-sepharose, or DEAE-Trisacryl is the most popular 
method designed to remove bulk impurities. DEAE-
cellulose (Guray & Arinc, 1990), agarose-hexane-NAD 
(Nisimoto et al., 1986), ADP-agarose (Zhang & Scott, 
1996), 5’-AMP-Sepharose (Tauber et al., 1985), blue-
Ultrogel (Galle et al., 1984), octylamino-Sepharose 
(Nisimoto et al., 1986), or blue 2-Sepharose (Madyastha 
et al., 1993) is used for intermediate purification steps. 
Agarose (Lee & Lee, 1994), Sephadex G-100 (Meldolesi 
et al., 1980), 5′-ADP-hexane-agarose (Kitajima et al., 
1981) hydroxyapatite (Lee et al., 1998; Nisimoto et al., 
1986), CM-Sephadex (Mihara & Sato, 1978), and NAD 
agarose (Meldolesi et al., 1980) are used in polishing 
steps to produce pure and active protein. Lysosome-
solubilized enzyme is obtained by the removing of 
the membrane-anchoring domain using cathepsin D 
(Iyanagi et al., 1984; Borgese et al., 1982), trypsin (Mihara 
& Sato, 1975), subtilisin (Kensil et al., 1983) or lyso-
somal protease (Tamura et al., 1983; Tamura et al., 1987; 
Takesue & Omura, 1970). Following this step, similar 
chromatographic steps to those used for soluble CyB5R 
are used to purify the soluble domain.
The native soluble CyB5R purification protocol is 
much simpler: the total soluble protein fraction is isolated 
from target tissues or recombinant clones and followed 
up with chromatography. One or two DEAE-cellulose 
or Q-sepharose steps are usually used to remove bulk 
impurities and are followed by polishing with amberlite 
CG-50, 5’-ADP-agarose, or sephadex G-100 (Arinc et al., 
1992; Mirzaei et al., 2010).
cyB5R assay
NADH-cytochrome b5 reductase is a multi-functional 
enzyme that catalyzes the redox reactions between 
NADH and CyB5. Several unique methods have been 
developed for measuring its activity.
Natural and artificial acceptors
NADH-cytochrome b5 reductase activity is usually mea-
sured usually by one of three different methods using 
potassium ferricyanide, cytochrome b5, or NADH-2,6-
dichlorophenol-indophenol (DCPIP) as an electron 
acceptor. DCPIP reductase activity was the earliest 
method developed. A reaction mixture consisting of 
0.1 mM DCPIP, 1 mM NADH, and an aliquot of enzyme 
fraction in a final volume of 2 ml of 100 mM potassium 
phosphate buffer (pH 7.5) is prepared. When the NADH 
is added, the change in absorption at 600 nm is recorded. 
The molar extinction coefficient of the oxidized dye at 
600 nm is assumed to be 21.0 mM−1cm−1. Enzyme activ-
ity is calculated according to the Bear-Lambert equation 
(A= εbc), and 1 unit of enzyme is defined as the amount 
required to reduce 1 μmol of DCPIP in 1 min (Miyake 
et al., 1975). The NADH-dependent ferricyanide reduc-
tion is carried out using 100 mM potassium phosphate 
buffer (pH 7.5) containing 1.0 mM NADH and 1.0 mM 
K
3
Fe(CN)
6
 and adequate enzyme solution in a final 
volume of 1 ml. A kinetic enzyme assay is initiated fol-
lowing the addition of NADH, and 1 unit of CyB5R 
activity is defined as the amount of enzyme required 
to reduce 1 μmol of ferricyanide in 1 minute. The activ-
ity of CyB5R with ferricyanide is assayed by measuring 
absorbance reduction at 420 nm (associated with iron 
reduction) or increased absorbance at 340 nm (associ-
ated with NADH oxidation), taking 1.02 mM−1cm−1 or 
6.25 mM−1cm−1 as the molar extinction coefficients, 
respectively. This is the simplest and most accurate assay 
for assessing CyB5R activity (Mirzaei et al., 2010). CyB5-
mediated reductase activity relies on an endogenous 
mechanism and is measured spectrophotometrically by 
the decrease in absorbance at 409 nm or the increased 
in absorbance at 423 nm. The reaction mixture contains 
10 pM CyB5, 100 μM NADH, an aliquot of enzyme frac-
tion, and potassium phosphate buffer (pH 7.2). For 
this assay, 1 unit of CyB5R is defined as the amount of 
enzyme that reduces 1 μmol of CyB5 in 1 min. The molar 
extinction coefficients of CyB5 at 423 nm and 409 nm are 
100 mM−1cm−1 and 117 mM−1cm−1, respectively (Tamura 
et al., 1983; Marohnic & Barber, 2001). According to the 
Lineweaver–Burk plot, the Km values for each substrate 
are determined from the intercept (−1/Km) of the plot 
of 1/ΔA versus [1/S] (Badwey et al., 1983). The true Kcat 
values for CyB5 reduction are determined by calculating 
the l/ν axis intercept of the l/ν versus l/[NADH] replot 
obtained using different CyB5 concentrations. ENZFIT 
(Elsevier, Biosoft. Ferguson, MO) is the most widely 
used and sophisticated software for calculating appar-
ent Km and Kcat values. Spectral binding constants, Ks, 
for the NADH are determined by differential spectro-
scopic titrations (Barber & Quinn, 2001). Absorbance 
changes versus nucleotide concentrations are plotted, 
and the resulting trend line is fitted to the following 
hyperbolic equation:
∆ ∆Absorbance
Ks nucleotide
 Absorbancemax 
nucleotide   
=
×[ ]÷ + ( ) 
The constant NAD(P)H specificity value is also cal-
culated as the ratio of (Kcat/KmNADH) ÷ (Kcat/KmNADPH) 
that represents the magnitude of NADH specificity of the 
enzyme toward NADPH.
The electrophoretic assay
The electrophoretic assay of CyB5R in gels (zymographic 
technique) was described by Kaplan and Beutler in 1967. 
Cell-free lysate is subjected to vertical native starch gel 
electrophoresis at 4°C and 100 mM phosphate buffer is 
used as the running buffer. Following electrophoresis, 
enzyme activity is measured using 1.2 mM 3-(4,5-dimeth-
ylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) 
together with 1.3 mM NADH and 0.06 mM DCPIP in a 
buffer of 250 mM Tris/HCl with a pH of 8.4 (Kaplan & 
Beutler, 1967).
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Radioimmunoblotting
For radioimmunoblotting, a specific CyB5R monoclonal 
antibody is blotted onto a nitrocellulose membrane. 
A solution containing CyB5R or normal hemolysate is 
allowed to interact with the membrane. The enzyme 
activity is initiated and measured when MTT is added in 
the presence of DCPIP and NADH. The resulting purple-
blue spots are then developed on each piece of nitrocel-
lulose (Lan et al., 1998).
Heterologous expression
Early studies on CyB5R relied on isolation of the native 
enzyme from either liver microsomes or erythrocytes. 
Many laborious purification steps must be carried out 
to extract the trace amounts of enzyme from the pool 
of proteins; however, most purification methods result 
in inadequate amounts and unacceptable purity. Once 
recombinant DNA and gene cloning technologies 
were developed and their use widened in the 1970s, 
all attention became focused on preparing proteins in 
heterologous hosts, and CyB5R was not an exception. 
Currently, 927 redundant CyB5R sequences, including 
481 from animals, 87 from fungi, 261 from plants, 90 from 
Trypanosomatidae, and 8 miscellaneous, are deposited 
in the National Center for Biotechnology Information 
(NCBI: http://www.ncbi.nlm.nih.gov); only 96 of these 
sequences have been verified by RefSeq. More recently, 
a variety of recombinant expression systems have been 
developed for the production of soluble and membrane-
bound variants following important advancements in 
protein expression and purification, for example, high 
level expression systems (Kimura et al., 2005); systems 
with low degradation (Shirabe et al., 1989); simple 
purification systems (Mirzaei et al., 2010); and muta-
genesis protocols (Marohnic et al., 2003). These expres-
sion systems used to study the structure (Bewley et al., 
2001), mechanism of action (Percy et al., 2005a), cancer 
(Belcourt et al., 1998), gene silencing (Zhuang et al., 
2008), and gene therapy (Lostanlen et al., 1981) of CyB5R. 
Recombinant E. coli has been the most widely used 
method for producing CyB5R and a wide array of suitable 
expression vectors have been generated including T7 
(Barber & Quinn, 1996), pET3c (Hyde & Campbell, 1990), 
pET23b (Percy et al., 2006a; Roma et al., 2006; Davis et al., 
2002), pET16b (Setayesh et al., 2009), pCP (Kimura et al., 
2005), λgt11 (Pietrini et al., 1988), and pUC13 (Shirabe 
et al., 1989). There are also reports of other methods 
used to express this protein, including yeast using pYES2 
(Hatanaka et al., 2004; Shockey et al., 2005), pPICZ 
(Mirzaei et al., 2010; Syed et al., 2011), and pRC/CMV 
(Belcourt et al., 1998); Aspergillus oryzae using pNGA142 
(Sakuradani et al., 1999); Salmonella typhimurium using 
pIN3 (Mokashi et al., 2003); Spodoptera frugiperda 
(Sf9) insect cells using pFASTBAC baculovirus vectors 
(Fukuchi-Mizutani et al., 1999); cell-free systems (Calza 
et al., 1987); plant cells using pRTL (Shockey et al., 2005); 
lymphoid cells using EBV (Lostanlen et al., 1981); and 
CHO cells using SV40 (Holtz et al., 2003). This protein 
has been reported in only eukaryotic species, and there 
are some reports of heterologous protein expression dif-
ficulties when using E. coli to express eukaryote-specific 
proteins (Sakuradani et al., 1999; Mirzaei et al., 2010). It 
appears that differences in codon usage are the largest 
obstacles in the efficient expression of eukaryotic pro-
teins in E. coli (Mirzaei, 2010).
Diseases related to cyB5R dysfunctions
Rapid oxidation of ferro-hemoglobins resulting from the 
rapid metabolism of radical forming agents, increased 
levels of oxidants due to the ingestion of toxic com-
pounds, hemoglobin M disorder, or familial reduced 
ability to regenerate methemoglobins to hemoglobins 
all lead to the manifestation of methemoglobinemia dis-
ease (Beauvais, 2000; Da-Silva et al., 2003). Familial met-
hemoglobinemia arising from mutations in CyB5R was 
the first idiopathic disease to be directly associated with 
an enzyme lesion or malfunction and was later defined 
as recessive congenital methemoglobinemia (RCM) or 
recessive hereditary methemoglobinemia (RHM). For 
100 years, the abnormalities relating to the disease were 
reported until in 1948, Gibson solved the puzzle of the 
first instance of a hereditary disease caused by specific 
enzyme deficiency (Gibson, 1948). Based on pathophysi-
ologic manifestations of the disease, two distinct clinical 
types of RCM have been classified. Type I RCM is a benign 
form of methemoglobinemia, with oxidized hemoglobin 
levels ranging from 10% to 40%, and a normal life expec-
tancy. The enzyme is produced at the normal rate but 
with a small number of amino acid substitutions. These 
substitutions cause protein instability such that the sol-
uble erythrocyte enzyme level is primarily affected. The 
predominant symptoms include well-tolerated cyanosis, 
fatigue, headache, and shortness of breath (Percy et al., 
2005b; Percy & Lappin, 2008; Ewenczyk et al., 2008). In 
contrast, type II RCM is a much more severe disorder 
with global loss of both membrane-bound and soluble 
enzyme in tissues and severe symptoms including life-
long cyanosis, progressive encephalopathy, mental 
retardation, microcephaly, dystonia, strabismus, failure 
to thrive, hypotrophy, profound cognitive impairment, 
and movement disorders, often leading to premature 
death (Leroux et al., 1975; Lawson et al., 1977). In this 
disease type, amino acid substitutions often occur in 
the catalytic domains, and the mutations can cause pre-
mature stop sites, frame-shift mutations, the omission 
of large protein segments or missplicing. To date, three 
known single nucleotide polymorphisms resulting in 
Arg59His, The117Ser, or Arg297His substitution (Jenkins 
& Prchal, 1997; Sacco & Trepanier, 2010) and 50 different 
mutations, from unrelated cases with RCM, have been 
published in the literature. Among the 43 exon muta-
tions, 26 have been associated with type I, 14 with type 
II, and 3 mutations were common to both types; for these 
3 mutations, the disease type depended on additional 
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Table 1. Naturally occurring mutations in the human CyB5R gene and the associated RCM type.
No Mutationsa Amino acid exchangeb Mutation positionb,c RCM typed References
1 CAG →TAG Q28 →@ Exon 2 Nu. 82 I (Fermo et al., 2008)
2 TAC →TAA Y43 →# Exon 2 Nu. 129 II (Manabe et al., 1996)
3 CGG →TGG R46 →W Exon 2 Nu. 136 I (Fermo et al., 2008)
4 CGG →CAG R50 →Q Exon 2 Nu. 149 I (Dekker et al., 2001)
5 AGC →AGG S54 →R Exon 3 Nu. 162 I (Percy & Lappin, 2008)
6 CGG →CAG R58 →Q Exon 3 Nu. 173 I (Shirabe et al., 1992)
7 CCG →CTG P65 →L Exon 3 Nu. 194 I (Dekker et al., 2001)
8 GGC →GC; Frame shifted; 130 amino 
acids fewer than the native protein
G72 →A Exon 3 Nu. 215 II (Hudspeth et al., 2010)
9 CTC →CCC L73 →P Exon 3 Nu. 218 I (Wu et al., 1998)
10 GGC →AGC G76 →S Exon 3 Nu. 226 I (Percy et al., 2006b)
11 CAG →TAG Q77 →@ Exon 4 Nu. 229 II (Aalfs et al., 2000)
12 CGA →TGA R84 →& Exon 4 Nu. 250 II (Higasa et al., 1998)
13 ATT →AGT I85 →S Exon 4 Nu. 254 I (Percy & Aslan, 2008)
14 CCC →CAC P96 →H Exon 4 Nu. 287 II (Manabe et al., 1996)
15 GTG →ATG V106 →M Exon 4 Nu. 316 I (Shirabe et al., 1992)
16 ATG →GTG M127 →V Exon 5 Nu. 379 II (Kugler et al., 2001)
17 TCT →CCT S128 →P Exon 5 Nu. 382 II (Kobayashi et al., 1990)
18 GGC →GAC G144 →D Exon 5 Nu. 431 I (Fermo et al., 2008)
19 CCC →TCC P145 →S Exon 5 Nu. 433 I (Fermo et al., 2008)
20 CCC →CTC P145 →L Exon 5 Nu. 434 I (Dekker et al., 2001)
21 CTG →CCG L149 →P Exon 5 Nu. 446 II (Davis et al., 2004)
22 TTT →TGT F157 →C Exon 6 Nu. 470 I (Lorenzo et al., 2011)
23 CGA →TGA R160 →& Exon 6 Nu. 478 I, II (Davis et al., 2004)
24 GCG →ACG A179 →T Exon 6 Nu. 535 I (Kugler et al., 2001)
25 GCG →GTG A179 →V Exon 6 Nu. 536 I (Dekker et al., 2001)
26 TGC →CGC C204 →R Exon 7 Nu. 610 II (Vieira et al., 1995)
27 TGC →TAC C204 →Y Exon 7 Nu. 611 I (Wang et al., 2000)
28 GAG →AAG E213 →K Exon 8 Nu. 637 I (Jenkins & Prchal, 1996)
29 ATC →ACC I216 →T Exon 8 Nu. 647 I (Grabowska et al., 2003)
30 CTG →CCG L217 →P Exon 8 Nu. 650 I (Nussenzveig et al., 2006)
31 CGA →TGA R219 →& Exon 8 Nu. 655 I, II (Vieira et al., 1995)
32 TGG →TGA W236 →& Exon 8 Nu. 708 II (Kedar et al., 2011)
33 CTG →CGG L239 →R Exon 8 Nu. 716 I (Dekker et al., 2001)
34 GAC →GGC D240 →G Exon 8 Nu. 719 I (Percy et al., 2005a)
35 AGA →GGA R241 →G Exon 8 Nu. 721 II (Toelle et al., 2004)
36 GTG →ATG V253 →M Exon 9 Nu. 757 I, II (Dekker et al., 2001)
37 GAG →Del E256 →Del Exon 9 Nu. 766-768 I (Percy et al., 2002)
38 CGG →TGG R259 →W Exon 9 Nu. 775 I (Maran et al., 2005)
39 ATG →Del M273 →Del Exon 9 Nu. 817-819 II (Vieira et al., 1995)
40 CCC →CTC P276 →L Exon 9 Nu. 827 I (Percy et al., 2006a)
41 GGC →GAC G292 →D Exon 9 Nu. 875 I (Percy et al., 2002)
42 CAC →AA; Frame shifted; 46 amino 
acids longer than the native protein
T295 →Del Exon 9 Nu. 883-885 II (Leroux et al., 2005)
43 TTC →Del F299 →Del Exon 9 Nu. 895-897 II (Shirabe et al., 1994)
44 A →G Exon 5 loss Intron 4 Nu. 418-2 II (Kugler et al., 2001)
45 G →A Exon 5 loss Intron 4 Nu. 418-1 I (Dekker et al., 2001)
46 A →C Exon 6 loss (28 amino 
acids lost)
Intron 5 Nu. 548-2 II (Maran et al., 2005)
47 T →C Exon 5 missplicing Intron 5 Nu. 547+2 II (Fermo et al., 2008)
48 G →C Exon 5 loss Intron 5 Nu. 547+8 II (Vieira et al., 1995)
49 G →A Exon 6 loss Intron 6 Nu. 631+1 I (Maran et al., 2005)
50 G →T Exon 9 missplicing Intron 8 Nu. 818-1 II (Shirabe et al., 1995)
aAssociated mutations in some cases are ignored to reduce table complexity.
b@, #, and & are standard stop codon symbols and “Nu” stands for “nucleotide”.
cFor convenience and homogeneity, some codons and amino acid numbers are revised. The last accepted membrane variant CyB5R3 refer-
ence sequence, NM_000398.6, comprises the 906 bp and 301 amino acids, including the initiator methionine.
dRCM phenotype depends on homozygosity/heterozygosity or other additional mutations.
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mutations or whether the mutation was homozygous. 
Most of the seven intronic mutations are associated with 
type II (Table 1).
Possible applications of cyB5R in 
biotechnology
The catalytic and electron transfer properties of CyB5R 
present possibilities for its application in the food 
industry, electrochemistry, and medicine. Industrially 
important lipids such as hydroxy, epoxy, conjugated, 
acetylenic and poly-unsaturated fatty acids are collected 
from plant (Shockey et al., 2005; Kumar et al., 2006) and 
fungal (Shimizu et al., 1997) species. Unfortunately, most 
of these species produce these oils in an inadequate sup-
ply. Recently, to increase essential fatty acids production 
and accumulation, many attempts have been made to 
increase levels of CyB5R by mutation or over-expression 
(Shockey et al., 2005; Kumar et al., 2006). Enzyme-based 
biosensors are rapid and robust methods for monitor-
ing the chemical potential of oxidation and reduction 
reactions, and these sensors could be used to diagnose 
methemoglobinemia levels in real-time (Bartlett, 2008). 
Additional research needs to be conducted to engineer 
and express CyB5R with the desired physicochemical 
properties for these industrial and clinical purposes. 
Studies of CyB5R will likely continue to increase quickly, 
particularly in efforts to identify new applications for this 
enzyme.
Future outlook and conclusion
This review was designed to provide a valuable synopsis 
of the current structural, functional, and mechanistic 
properties of CyB5R, in addition to describing the known 
mutations associated with the human disease recessive 
congenital methemoglobinemia. These data also support 
the use of the enzyme kinetics and potential applications. 
Investigation of the primary structures of different CyB5R 
variants has revealed strong sequence similarities, the 
domains involved in electron transport, and the motifs 
involved in FAD-cofactor and NADH-coenzyme bind-
ing. Despite the tremendous amount of work already 
conducted, mainly involving the soluble or truncated 
soluble enzyme, several fundamental issues remain to 
be addressed, including the structure, interactions, and 
mechanism of function of the entire membrane variant 
of CyB5R. Recent progress in solid-state NMR for molec-
ular biology, biochemical and structural investigations 
may aid in answering most of these remaining questions. 
The major constraint on this project is the development 
of an effective, robust, inexpensive, and potent expres-
sion system for labeled membrane protein production. 
Our preliminary research and many other investigations 
have shown that Pichia pastoris can be used to express 
and secrete sufficient amount of heterologous mem-
brane CyB5R; however, the most important obstacle for 
membrane protein NMR is the production of protein 
with correct folding and uniform labeling. Thus, efforts 
have to be made to achieve these goals, and our research 
group is currently focused on this field of research.
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